Clinical study on cetuximab combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer

Jian-ping HU,An-rong MAO,Hai-bei XIN,He HUANG

DOI: https://doi.org/10.7501/j.issn.1674-5515.2017.03.034

2017-01-01

Abstract:Objective To investigate the clinical effect of Cetuximab Solution for infusion combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer.Methods Patients (75 cases) with metastatic colorectal cancer in 85 Hospital of People's Liberation Army from June 2014 to December 2015 were randomly divided into the control group (37 cases) and the treatment group (38 cases). Patients in the control group were treated with FOLFOX4 chemotherapy and iv administered with Oxaliplatin for injection in the first day treatment, 85 mg/m2 added into normal saline 250 mL. And they were also iv administered with Fluorouracil Injection in the first and second day treatment, 300 mg/m2 added into normal saline 250 mL. In the same time, patients in the control group were iv administered with Calcium Folinate Injection in the first and second day treatment, 400 mg/m2 added into normal saline 250 mL. Patients in the treatment group were iv administered with Cetuximab Solution for infusion on the basis of the control group, 500 mg/m2, intravenous infusion of 2 h at the first time, followed by intravenous infusion of 1 h, once weekly. Patients in two groups were treated for 4 courses, 2 weeks as one course. After treatment, the clinical efficacies were evaluated, and tumor marker levels and adverse reactions in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 40.5% and 52.6%, respectively, the disease control rates in two groups were 70.3% and 89.5%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of CEA and CA199 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). The total incidence of skin rash in the control and treatment groups were 8.11% and 34.2%, respectively, and there was difference between two groups (P < 0.05). But the other adverse reactions had no significant difference between two groups.Conclusion Cetuximab Solution for infusion combined with FOLFOX4 chemotherapy has clinical curative effect in treatment of metastatic colorectal cancer, can decrease tumor marker levels with good safety, which has a certain clinical application value.